Altai Protocol Library
1041 protocols and counting
All protocols with references and links
All protocols reviewed by a Medical Oncologist/Hematologist
All protocols in major guidelines included
Ability to create your own protocols
New Protocol: Lenvatinib for advanced grade 1/2 pancreatic and GI neuroendocrine tumors
Study: Open-label phase II trial (TALENT) Advanced pancreatic (panNET) or gastrointestinal (GI-NET), grade 1/2 neuroendocrine tumor progressed on a targeted agent (pancreatic) or somatostatic analog (GI) Lenvatinib 24 mg PO
New Protocol: Vemurafenib + riTUXimab for hairy cell leukemia
Study: Phase II single-center trial (HCL-PG03) Refractory or relapsed hairy cell leukemia with b-raf V600E mutation Total of 18 wks of therapy including vemurafenib 960 mg BID x 8 wks
New Indication: Pembrolizumab for her2-positive gastric/GEJ adenoCa
Study: Randomized, double-blind phase III study (KEYNOTE-811) First-line treatment for metastatic her2-positive gastric or GEJ adenocarcinoma Chemotherapy + trastuzumab + pembrolizumab (n=133) vs. chemotherapy + trastuzumab + placebo (n=131) Chemotherapy:
New Indication: Adjuvant nivolumab for esophageal / GEJ cancer
Study: Randomized, double-blind, placebo controlled phase III (CheckMate 577) Resected stage II/III esophageal or gastroesophageal junction cancer (R0) who had received neoadjuvant chemoradiotherapy and NOT achieved pathological CR Adjuvant nivolumab
New Indication: Neoadjuvant FOLFIRINOX for locally advanced rectal cancer
Study: Randomized, open-label phase III (UNICANCER-PRODIGE 23) Newly diagnosed cT3/T4M0 rectal adenoCa Arm A: 6 cycles of FOLFIRINOX => Chemoradiotherapy (50 Gy with capecitabine) => Surgery => Adjuvant chemo (mFOLFOX6
New Drug: Infigratinib for FGFR2+ cholangiocarcinoma
Study: Single-arm phase II study (BGJ398) Advanced/metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements with progression on >= 1 line Infigratinib 125 mg PO daily (21/28 days) Efficacy: ORR: 23.1% [15.6%-32.2%] Median DoR:
New Drug: Amivantamab for EGFR Exon 20 Insertion Mutant NSCLC post-platinum
Study: Single-arm phase II study (CHRYSALIS) Advanced/metastatic NSCLC (EGFR Exon20ins) second-line post-platinum chemo Amivantamab single agent Efficacy: ORR: 36% [25%-47%] Median DoR: 6.8 mos [5.0 mos – NR] Median PFS:
New Drug: Sotorasib for k-ras G12C mutated NSCLC
Study: Single-arm phase II study (CodeBreaK 100, phase II part) Locally advanced or metastatic k-ras G12C mutant non-small cell lung cancer, progressed on anti-PD-1/PD-L1 and/or platinum-based combination chemotherapy AND targeted
New Protocol: Isatuximab – carfilzomib – dexamethasone for relapsed/refractory multiple myeloma
Study: Randomized phase III study (IKEMA) Relapsed/refractory multiple myeloma with >=2 prior lines including lenalidomide and a proteasome inhibitor Isatuximab + carfilzomib + dexamethasone (n=179) vs. carfilzomid + dexamethasone (n=123)
New Drug: Dostarlimab for advanced dMMR endometrial cancer
Study: Open-label phase I study (GARNET) Recurrent or advanced endometrial cancer that progressed on/after platinum-based regimen Dostarlimab in MMR deficient (dMMR, n = 103) and MMR proficient (MMRp, n =
New Reference: Sacituzumab govitecan for metastatic triple-negative breast cancer
Study: Open-label, randomized phase III trial (ASCENT) Metastatic triple-negative breast cancer, relapsed or refractory to >=2 regimens (had to include a taxane) Sacituzumab govitecan (n=235) vs. single-agent chemotherapy [eribulin, vinorelbine,
New Protocol: Trastuzumab deruxtecan for her2+ metastatic colorectal cancer
Study: Open-label phase II trial (DESTINY-CRC01) Her2 overexpressing metastatic colorectal cancer that progressed on >=2 regimens Cohort A: IHC 3+ or ISH-positive (n=53) analyzed Trastuzumab deruxtecan 6.4 mg/kg IV q21d
New Protocol: Copanlisib + riTUXimab for indolent NHL
Study: Double-blind, randomized, placebo-controlled phase III trial (CHRONOS-3) CD20+ indolent non-Hodgkin lymphoma relapsed after last anti-CD20 containing therapy Copanlisib + riTUXimab vs. placebo + riTUXimab Efficacy: CR: 34% vs. 15%
New Protocol: Romidepsin and oral azacytidine for PTCL
Study: Multi-center, phase II study Treatment-naïve (n= 10) or relapsed/refractory (n=13) peripheral T-cell lymphoma Oral azacytidine 300 daily (d1-14) + romidepsin IV on days 8,15,22 (35 day cycle) Efficacy: CR:
New Protocol: Ivosidenib + chemotherapy for IDH-mutated AML
Study: Phase I, multi-center, open-label study Newly diagnosed acute myeloid leukemia with mutated IDH1 or IDH2 Continuous ivosidenib (mIDH1) or enasidenib (mIDH2) with induction 7 + 3 chemo Efficacy: CR:
New Indication: FOLFOX for second-line advanced biliary tract cancer
Study: Phase III, open-label, randomized trial (ABC-06) Locally advanced or metastatic biliary tract cancer with progression to CISplatin – gemcitabine FOLFOX-6 vs. active symptom control Efficacy: FOLFOX group => ORR:
New Drug: Loncastuximab tesirine for relapsed/refractory DLBCL
Study: Open-label phase II study (LOTIS-2) Relapsed/refractory diffuse large B-cell lymphoma with >=2 prior therapies Loncastuximab q3wk (N=145) Efficacy: CRR: 24.1%, ORR: 48.3% Median DoR: 10.3 mos ORR among double/triple-hit:
New Indication: Sacituzumab govitecan for advanced urothelial cancer
Study: Open-label phase II trial (TROPHY-U-01). Cohort 1 results Unresectable locally advanced or metastatic urothelial cancer progressed after CISplatin and checkpoint inhibitors Sacituzumab govitecan 10 mg/kg on days 1,8 (21d)
New Reference: Nivolumab + cabozantinib for previously untreated advanced clear cell renal cell carcinoma
Study: Randomized, open-label phase III trial (TIVO-3) Previously untreated RCC with clear cell component Cabozantinib 40 daily + nivolumab 240 q14 (n=323) vs. sunitinib 50 daily 4/6 wks (n=328), all